Experimental Immunotherapy Makes Headway in Lung Cancer
June 28, 2012|Oncology Practice
Author and Disclosure Information
AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Clinical registration trials of BMS-936558 in patients with NSCLC are planned, Dr. Brahmer said. Recruitment is already underway for a multiarm study of BMS-936558 in combination with three platinum-based doublet chemotherapy regimens in treatment-naïve, stage IIIB/IV NSCLC.
Bristol-Myers Squibb sponsored the study. Dr. Brahmer and Dr. Giaccone report no relevant disclosures.
